Lantern Pharma (LTRN) investor relations material

AI-driven drug development and clinical progress

• AI platform RADR® has reduced drug-to-clinic timelines by 70%-80%, enabling rapid patient dosing and trial advancement.

• AI predictions have accurately identified patient subgroups and biomarkers, improving trial success rates and reducing costs by 30%-50%.

• Over 10 programs launched in the past two years, with multiple drugs in phase I and II trials, including LP-300, LP-184, and LP-284.

• AI-driven indication selection and mechanism discovery have led to fast track and orphan designations for several assets.

• Collaborations with pharma and research institutions leverage the platform for equity, IP, and development rights.

Platform innovation and commercialization

• RADR® integrates over 500 billion data points and hundreds of algorithms, supporting end-to-end oncology drug discovery.

• New platforms PredictBBB.ai and withZeta.ai offer molecular characterization and co-scientist capabilities, now available to the public.

• withZeta.ai enables real-time drug design, biomarker analysis, and knowledge graph creation, accelerating R&D cycles from months to minutes.

• Plans to monetize withZeta.ai via subscription, targeting pharma and researchers, with a focus on rare cancers.

• The platform has enabled the development of seven new drugs in 90 days, with ongoing expansion of the portfolio.

Pipeline highlights and financial outlook

• 12 FDA designations achieved, including six orphan and two fast track, with recent success in adult sarcomas and brain cancers.

• Starlight Therapeutics, a new subsidiary focused on brain cancer, is advancing through phase I-B and II trials, with plans for independent financing.

• LP-300 and LP-184 are key near-term catalysts, with clinical data and trial launches expected within the next 30 days.

• Burn rate is $4 million per quarter, with $12 million in capital, no debt, and funding through Q3.

• Strategy centers on out-licensing assets post-proof-of-concept, leveraging innovation for value creation.